Potential effects of decreased cervical cancer screening participation after HPV vaccination: An example from the U.S.

Vaccine

Volumn 25, Issue 48, 2007, Pages 8110-8113

  Kulasingam, Shalini L ^a   Pagliusi, Sonia ^b   Myers, Evan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Digene Switzerland   (Switzerland)

Author keywords

Cervical cancer screening; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DISEASE COURSE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PUBLIC HEALTH; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 35748982428     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.035     Document Type: Article

References (17)

1. Kitchener H.C., Castle P.E., and Cox J.T. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 24 Suppl. 3 (2006) S63-S70
2. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 (2003) 101-105
3. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 (2003) 63-73
4. Mosher W.D., Chandra A., and Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data (2005) 1-55
5. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738
6. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
7. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
8. Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
9. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 (2005) S7-S11
10. Solomon D., Breen N., and McNeel T. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 57 (2007) 105-111
11. Coughlin S.S., King J., Richards T.B., and Ekwueme D.U. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000-2002. Cancer Epidemiol Biomarkers Prev 15 (2006) 2154-2159
12. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
13. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
14. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. EID 13 (2007) 28-40
15. Myers E.R., McCrory D.C., Nanda K., Bastian L., and Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151 (2000) 1158-1171
16. Peto J., Gilham C., Deacon J., Taylor C., Evans C., Binns W., et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91 (2004) 942-953
17. Franco E.L., Cuzick J., Hildesheim A., and de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 Suppl. 3 (2006) S171-S177